CatalystMarker
Sign in
← board

JNJ

Janssen Research & Development, LLCdistress 0/10 · well-funded / low risk
$256.46+0%today-4% from 52w high
jnj.com138,200 employeesFounded 1886New Brunswick, NJDrug Manufacturers - General
Neurology 1
Lead: Multiple Myeloma · est. market ~$25B (approx, global)
Revenue
$24062M
Liquidity
$22051M
Runway
—
Shares 1y
0%

Price & events

+18.7% over 6M
$216$242$267Jan 26Apr 26Jul 2619.0Mdilution: S-3ASR shelf_registration (2026-02-11)rating: Guggenheim: Buy (2026-07-17)rating: Raymond James: Outperform (2026-07-16)rating: Morgan Stanley: Overweight (2026-07-16)rating: Wells Fargo: Overweight (2026-07-16)rating: RBC Capital: Outperform (2026-07-16)rating: RBC Capital: Outperform (2026-07-13)rating: TD Cowen: Buy (2026-07-13)rating: B of A Securities: Neutral (2026-07-10)
CatalystRating changeDilutionFinancingdashed = today
+0.3%
1D
+2.6%
1W
+7.3%
1M
+11.8%
3M
+17.8%
6M
+55.5%
1Y
+78.2%
2Y
+71.8%
5Y
+91.0%
All

Overview

Market Cap
$617.35B
Enterprise Value
$633.19B
Volume
670.23K
52 Week Range
$155 – $267
Total Shares
2.41B
Float Shares
2.40B
Short %
1.23%
% Held by Insiders
0.05%
% Held by Institutions
76.86%
RVOL
0.08x
Beta
0.23

Pipeline stages · 27 programs

Guselkumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-03-25
Daratumumab, Carfilzomib, Dexamethasone
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-04-07
JNJ-81201887
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-04-14
Amivantamab, Pembrolizumab, Carboplatin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-04-27
Nipocalimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-05-14
AAV5-hRKp.RPGR
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-06-30
Talquetamab, Prophylaxis A, Prophylaxis B
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-06-30
Pasritamig, Best Supportive Care (BSC)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-08-31
Ustekinumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-09-29
Ibrutinib, Venetoclax
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-12-15
Show all 27 programs · 17 more ▾
Nipocalimab, Intravenous immunoglobulins (IVIG), Prednisone
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-12-15
Ramantamig, Daratumumab, Lenalidomide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-12-31
Icotrokinra
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-01-14
Erdafitinib Intravesical Delivery System
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-03-30
TAR-200, Mitomycin C, Gemcitabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-04-06
Cilta-cel, Talquetamab, Daratumumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-04-12
Gemcitabine, MMC
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-06-28
JNJ-90301900 (NBTXR3), Cetuximab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-06-30
Seltorexant
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-08-24
methoxsalen, Vedolizumab, Infliximab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-12
Prizloncabtagene autoleucel (Prizlo-Cel)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-12-29
JNJ-90301900, Durvalumab, Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-12-31
Bortezomib, Dexamethasone, Lenalidomide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-02-14
Bleximenib, Venetoclax (VEN), Azacitidine (AZA)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-06-22
LHRHa, Apalutamide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-08-27
Esketamine, Midazolam
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2031-04-09
Teclistamab, Daratumumab, Lenalidomide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2031-04-30

Pipeline · 80 trials · 80 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2027-03-25
Estimated 50%
readout ~2027-06-08
Phase 3GuselkumabFistulizing Crohns Disease, Perianal Crohns Disease—active not recruiting
2027-04-07
Estimated 50%
readout ~2027-05-07
Phase 1Daratumumab, Talquetamab, TeclistamabMultiple Myeloma—active not recruiting
2027-04-14
Estimated 50%
readout ~2027-05-14
Phase 1JNJ-86974680, CetrelimabCarcinoma, Non-small-Cell Lung—recruiting
2027-04-19
Estimated 50%
readout ~2027-05-19
Phase 1JNJ-79635322Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis—recruiting
2027-04-27
Estimated 50%
readout ~2027-06-11
Phase 1/2Amivantamab IV, Fluorouracil, LeucovorinAdvanced or Metastatic Colorectal Cancer—recruiting
Show all 80 trials · 75 more ▾
ReadoutPhaseDrugIndicationEnrollStatus
2027-05-14
Estimated 50%
readout ~2027-07-28
Phase 2/3NipocalimabPolyradiculoneuropathy, Chronic Inflammatory Demyelinating—recruiting
2027-05-31
Estimated 50%
readout ~2027-07-15
Phase 2Amivantamab IV, Amivantamab SC, LazertinibCarcinoma, Non-Small-Cell Lung—active not recruiting
2027-06-08
Estimated 50%
readout ~2027-08-22
Phase 3GuselkumabCrohn's Disease—active not recruiting
2027-06-14
Estimated 50%
readout ~2027-07-29
Phase 2JNJ-79635322Multiple Myeloma—recruiting
2027-06-21
Estimated 50%
readout ~2027-07-21
Phase 1JNJ-78278343, JNJ-87189401, ApalutamideProstatic Neoplasms—recruiting
2027-06-28
Estimated 50%
readout ~2027-08-12
Phase 2JNJ-88545223Arthritis, Psoriatic—recruiting
2027-06-30
Estimated 50%
readout ~2027-08-14
Phase 2TalquetamabHematological Malignancies—recruiting
2027-06-30
Estimated 50%
readout ~2027-09-13
Phase 3AAV5-hRKp.RPGRRetinitis Pigmentosa—active not recruiting
2027-07-15
Estimated 50%
readout ~2027-08-14
Phase 1JNJ-89853413Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms—active not recruiting
2027-07-30
Estimated 50%
readout ~2027-10-13
Phase 3Talquetamab, Daratumumab, PomalidomideMultiple Myeloma—active not recruiting
2027-08-05
Estimated 50%
readout ~2027-10-19
Phase 3NipocalimabHemolytic Disease of the Fetus and Newborn—recruiting
2027-08-05
Estimated 50%
readout ~2027-09-04
Phase 1JNJ-90189892, Azacitadine (AZA), Venetoclax (VEN)Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms—recruiting
2027-08-17
Estimated 50%
readout ~2027-10-01
Phase 2Amivantamab, Lazertinib, CarboplatinCarcinoma, Non-small-Cell Lung—recruiting
2027-08-31
Estimated 50%
readout ~2027-09-30
Phase 1Pasritamig, Cetrelimab, CabazitaxelMetastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer—recruiting
2027-09-28
Estimated 50%
readout ~2027-12-12
Phase 3Nipocalimab, EfgartigimodMyasthenia Gravis—recruiting
2027-09-29
Estimated 50%
readout ~2027-12-13
Phase 3UstekinumabCrohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic—active not recruiting
2027-10-27
Estimated 50%
readout ~2028-01-10
Phase 3GuselkumabCrohn's Disease—recruiting
2027-10-29
Estimated 50%
readout ~2027-11-28
Phase 1JNJ-88998377Lymphoma, Non-Hodgkin, Refractory B-Cell NHL, Relapsed B-cell NHL—active not recruiting
2027-11-03
Estimated 50%
readout ~2027-12-03
Phase 1JNJ-87562761Relapsed or Refractory Multiple Myeloma—active not recruiting
2027-11-18
Estimated 50%
readout ~2027-12-18
Phase 1JNJ-95437446Colorectal Neoplasms—recruiting
2027-11-19
Estimated 50%
readout ~2028-02-02
Phase 3Pasritamig, Docetaxel, PrednisoneProstatic Neoplasms, Castration-Resistant—recruiting
2027-11-19
Estimated 50%
readout ~2027-12-19
Phase 1JNJ-79635322, Daratumumab, PomalidomideMultiple Myeloma—recruiting
2027-12-15
Estimated 50%
readout ~2028-02-28
Phase 3Amivantamab, Cetuximab, BevacizumabColorectal Neoplasms—recruiting
2027-12-15
Estimated 50%
readout ~2028-01-29
Phase 2Ibrutinib, VenetoclaxLeukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma—recruiting
2027-12-15
Estimated 50%
readout ~2028-02-28
Phase 3Nipocalimab, Intravenous immunoglobulins (IVIG), PrednisoneThrombocytopenia, Neonatal Alloimmune—recruiting
2027-12-27
Estimated 50%
readout ~2028-02-10
Phase 1/2Amivantamab, Pembrolizumab, PaclitaxelSquamous Cell Carcinoma of Head and Neck—recruiting
2027-12-29
Estimated 50%
readout ~2028-03-13
Phase 3Pasritamig, Best Supportive Care (BSC)Metastatic Castration-resistant Prostate Neoplasms—recruiting
2027-12-31
Estimated 50%
readout ~2028-02-14
Phase 2Ramantamig, TocilizumabMultiple Myeloma—not yet recruiting
2028-01-01
Estimated 50%
readout ~2028-03-16
Phase 3Nipocalimab, Standard of care treatmentSjogrens Syndrome—active not recruiting
2028-01-12
Estimated 50%
readout ~2028-02-11
Phase 1JNJ-1761981, CetrelimabNeoplasms—recruiting
2028-01-14
Estimated 50%
readout ~2028-03-29
Phase 3IcotrokinraColitis, Ulcerative—recruiting
2028-01-19
Estimated 50%
readout ~2028-02-18
Phase 1JNJ-75348780, JNJ-67856633, JNJ-54179060Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Solid Tumor, Adult, Prostatic Neoplasms, Castration-Resistant—enrolling by invitation
2028-02-25
Estimated 50%
readout ~2028-03-26
Phase 1JNJ-89402638, Bevacizumab, FOLFOXColorectal Neoplasms, Gastrointestinal Neoplasms—recruiting
2028-03-02
Estimated 50%
readout ~2028-04-16
Phase 2Amivantamab, Lazertinib, CarboplatinCarcinoma, Non-Small-Cell Lung—not yet recruiting
2028-03-30
Estimated 50%
readout ~2028-05-14
Phase 1/2Erdafitinib Intravesical Delivery SystemNon-Muscle Invasive Bladder Neoplasms—recruiting
2028-04-06
Estimated 50%
readout ~2028-06-20
Phase 3TAR-210, Mitomycin C, GemcitabineNon-Muscle Invasive Bladder Neoplasms—recruiting
2028-04-12
Estimated 50%
readout ~2028-05-27
Phase 2Cilta-cel, Cyclophosphamide, Induction therapyMultiple Myeloma—recruiting
2028-06-12
Estimated 50%
readout ~2028-08-26
Phase 3JNJ-78934804, GuselkumabCrohn Disease—recruiting
2028-06-28
Estimated 50%
readout ~2028-09-11
Phase 3Gemcitabine, MMCNon-Muscle Invasive Bladder Neoplasms—recruiting
2028-06-30
Estimated 50%
readout ~2028-09-13
Phase 3JNJ-90301900 (NBTXR3), CetuximabCarcinoma, Squamous Cell—recruiting
2028-07-14
Estimated 50%
readout ~2028-08-13
Phase 1JNJ-90301900, Cisplatin, CarboplatinSquamous Cell Carcinoma of Head and Neck—recruiting
2028-08-11
Estimated 50%
readout ~2028-10-25
Phase 3JNJ-78934804, GuselkumabColitis, Ulcerative—recruiting
2028-08-24
Estimated 50%
readout ~2028-11-07
Phase 3SeltorexantDepressive Disorder, Major—recruiting
2028-08-31
Estimated 50%
readout ~2028-09-30
Phase 1JNJ-95566692, JNJ-87801493Lymphoma, Non-Hodgkin—recruiting
2028-09-19
Estimated 50%
readout ~2028-12-03
Phase 2/3IcotrokinraCrohn Disease—recruiting
2028-11-08
Estimated 50%
readout ~2028-12-08
Phase 1JNJ-87704916, Cetrelimab, Standard of Care PD(L)-1Neoplasms—recruiting
2028-11-15
Estimated 50%
readout ~2029-01-29
Phase 3Guselkumab, RisankizumabCrohn Disease—recruiting
2028-11-30
Estimated 50%
readout ~2029-01-14
Phase 1/2Amivantamab, OlomorasibCarcinoma, Non-Small-Cell Lung—recruiting
2028-12
Estimated 50%
readout ~2029-01-15
Phase 2methoxsalen, Vedolizumab, InfliximabColitis, Hepatitis, Melanoma (Skin Cancer)—not yet recruiting
2028-12-06
Estimated 50%
readout ~2029-02-19
Phase 3Nipocalimab, Standard of care treatmentLupus Erythematosus, Systemic—recruiting
2028-12-08
Estimated 50%
readout ~2029-02-21
Phase 3Daratumumab, Pomalidomide, DexamethasoneMultiple Myeloma—active not recruiting
2028-12-12
Estimated 50%
readout ~2029-02-25
Phase 3JNJ-79635322, TeclistamabMultiple Myeloma—recruiting
2028-12-15
Estimated 50%
readout ~2029-02-28
Phase 3Amivantamab, Cetuximab, 5-fluorouracilColorectal Neoplasms—recruiting
2028-12-29
Estimated 50%
readout ~2029-02-12
Phase 1/2Prizloncabtagene autoleucel (Prizlo-Cel)Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse—recruiting
2028-12-31
Estimated 50%
readout ~2029-02-14
Phase 2JNJ-90301900, Durvalumab, Concurrent Chemo/Radiation Therapy (cCRT): CarboplatinCarcinoma, Non-Small-Cell Lung—recruiting
2029-01-31
Estimated 50%
readout ~2029-04-16
Phase 3Daratumumab, Carfilzomib, DexamethasoneMultiple Myeloma—recruiting
2029-02-14
Estimated 50%
readout ~2029-04-30
Phase 3Bortezomib, Dexamethasone, LenalidomideMultiple Myeloma—active not recruiting
2029-04-29
Estimated 50%
readout ~2029-07-13
Phase 3JNJ-79635322, TeclistamabMultiple Myeloma—recruiting
2029-05-18
Estimated 50%
readout ~2029-06-17
Phase 1JNJ-95804306, AML SoC, CLL/SLL SoCHematologic Neoplasms—recruiting
2029-05-23
Estimated 50%
readout ~2029-07-07
Phase 2Amivantamab, Lazertinib, Chemotherapy: PemetrexedCarcinoma, Non-Small-Cell Lung—recruiting
2029-06-18
Estimated 50%
readout ~2029-09-01
Phase 3Amivantamab, Pembrolizumab, CarboplatinSquamous Cell Carcinoma of Head and Neck—recruiting
2029-06-22
Estimated 50%
readout ~2029-09-05
Phase 3Bleximenib, Venetoclax (VEN), Azacitidine (AZA)Leukemia, Myeloid, Acute—recruiting
2029-08-24
Estimated 50%
readout ~2029-10-08
Phase 2JNJ-81201887Geographic Atrophy, Macular Degeneration—recruiting
2029-08-27
Estimated 50%
readout ~2029-11-10
Phase 3LHRHa, ApalutamideProstatic Neoplasms—active not recruiting
2029-09-18
Estimated 50%
readout ~2029-12-02
Phase 3TAR-200, Cetrelimab, BCG VesicultureBladder Cancer—active not recruiting
2029-09-20
Estimated 50%
readout ~2029-12-04
Phase 3AAV5-hRKp.RPGR Intermediate Dose, AAV5-hRKp.RPGR Low DoseX-Linked Retinitis Pigmentosa—active not recruiting
2029-12-05
Estimated 50%
readout ~2030-02-18
Phase 3NipocalimabThrombocytopenia, Neonatal Alloimmune—recruiting
2030-05-30
Estimated 50%
readout ~2030-07-14
Phase 2Talquetamab, Prophylaxis A, Prophylaxis BMultiple Myeloma—recruiting
2030-09-02
Estimated 50%
readout ~2030-10-17
Phase 2Cilta-cel, Talquetamab, DaratumumabMultiple Myeloma—active not recruiting
2030-09-04
Estimated 50%
readout ~2030-11-18
Phase 3Ramantamig, Daratumumab, LenalidomideMultiple Myeloma—not yet recruiting
2030-10-24
Estimated 50%
readout ~2030-12-08
Phase 2AAV5-hRKp.RPGRX-Linked Retinitis Pigmentosa—active not recruiting
2030-11-27
Estimated 50%
readout ~2031-02-10
Phase 3TAR-200, Mitomycin C, GemcitabineNon-Muscle Invasive Bladder Neoplasms—active not recruiting
2031-04-09
Estimated 50%
readout ~2031-06-23
Phase 3Esketamine, MidazolamDepressive Disorder, Major—recruiting
2031-04-30
Estimated 50%
readout ~2031-07-14
Phase 3Teclistamab, Daratumumab, LenalidomideMultiple Myeloma—recruiting
2031-12-12
Estimated 50%
readout ~2032-02-25
Phase 3GuselkumabCrohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile—recruiting

Catalyst news & presentations · 2

Approved drugs (14)

  • ICOTYDEICOTROKINRA HYDROCHLORIDE2026 · Prescription
  • RYBREVANT FASPROAMIVANTAMAB AND HYALURONIDASE-LPUJ2026 · Prescription
  • RYBREVANT FASPROAMIVANTAMAB AND HYALURONIDASE-LPUJ2025 · Prescription
  • INLEXZOGEMCITABINE HYDROCHLORIDE2025 · Prescription
  • IMAAVYNIPOCALIMAB-AAHU2025 · Prescription
  • LAZCLUZELAZERTINIB MESYLATE2024 · Prescription
  • AKEEGAABIRATERONE ACETATE2023 · Prescription
  • TALVEYTALQUETAMAB-TGVS2023 · Prescription
  • TECVAYLITECLISTAMAB-CQYV2022 · Prescription
  • XARELTORIVAROXABAN2021 · Prescription

Capital structure — dilution & financing

Shares out: 2,407,216,971 · 0 offerings/1y · 0 PIPEs
  • 2026-02-11S-3ASRshelf_registration
  • 2025-02-21424B2offering
  • 2025-02-19424B5offering
  • 2025-02-19FWPoffering
  • 2025-02-19424B2offering
  • 2025-02-18424B5offering
  • 2025-02-18FWPoffering
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

buy · target $270 (+5% upside) · 22 analysts
  • 2026-07-17GuggenheimBuy
  • 2026-07-16Raymond JamesOutperform
  • 2026-07-16Morgan StanleyOverweight
  • 2026-07-16Wells FargoOverweight
  • 2026-07-16RBC CapitalOutperform
  • 2026-07-13RBC CapitalOutperform

Competitors — Multiple Myeloma

  • ABBVAbbVie Inc.$451.1B · D2
  • GSKGSK plc$217.0B · D1
  • PFEPFIZER INC$142.2B · D3
  • BMYBRISTOL MYERS SQUIBB CO$124.5B · D0
  • REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
  • CCCCC4 Therapeutics, Inc.$408M · D5
  • DTILPRECISION BIOSCIENCES INC$185M · D6
  • CRBUCaribou Biosciences, Inc.$160M · D0
  • TPSTTempest Therapeutics, Inc.$14M · D10
  • AZNASTRAZENECA PLC— · D3

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.